- Conditions
- Parkinson's Disease
- Interventions
- E2007
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 61
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Parkinson's Disease, Motor Fluctuations
- Interventions
- DM-1992, Sinemet IR
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 4 more
- Conditions
- Parkinson's Disease
- Interventions
- PF-06649751
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
- Conditions
- Parkinson Disease
- Interventions
- Opicapone
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
- Conditions
- Parkinson's Disease
- Interventions
- DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
- Drug
- Lead sponsor
- Dart NeuroScience, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Tozadenant
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- CVN424 75 mg, CVN424 150 mg, Placebo
- Drug
- Lead sponsor
- Cerevance
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
- Drug · Other
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
- Conditions
- Parkinson Disease
- Interventions
- AP-472, Placebo
- Drug · Other
- Lead sponsor
- Appello Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- Placebo, UCB0022
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
- Interventions
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
- Conditions
- Parkinson's Disease
- Interventions
- levetiracetam, Placebo
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 30 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Parkinson's Disease
- Interventions
- XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
- Conditions
- Advanced Stage Parkinson's Disease
- Interventions
- Levodopa (Pardoprunox), Placebo Comparator
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 12 more
- Conditions
- Parkinson's Disease
- Interventions
- Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Peoria, Arizona • Bingham Farms, Michigan
- Conditions
- Parkinson Disease
- Interventions
- Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Interventions
- clartihromycin, amoxicillin, and omeprazole, placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson Disease
- Interventions
- Lenrispodun, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more
- Conditions
- Parkinson's Disease With Motor Fluctuations
- Interventions
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 87 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more
- Conditions
- Parkinson's Disease, Levodopa
- Interventions
- Erythromycin, placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Parkinson's Disease, Off Episodes of Parkinson Disease
- Interventions
- APL-130277, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
- Conditions
- Parkinson's Disease
- Interventions
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 7
- States / cities
- Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
- Interventions
- SER-252 (PEOZ-apomorphine), enFuse
- Drug · Device
- Lead sponsor
- Serina Therapeutics
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more